On February 10, vTv Therapeutics announced positive study results from the second part of the Phase 2 Simplici-T1 Study of TTP399.

Dexcom CEO Kevin Sayer discusses Dexcom’s international strategy, the next-generation Dexcom G7, and the response to the Dexcom Follow outage last Fall.

Here, you'll find continuous updates on the status of the diabetes supply chain, with up to date information from all major insulin and device manufacturers as it relates to COVID-19.

Dr. Anne Peters, a clinical diabetologist at the USC, recently took the time to answer questions about COVID-19 sourced from the Beyond Type 1 community.

Do you think you've contracted coronavirus? Here are immediate steps to take to ensure you best treat yourself and limit the impact you have on those around you.

Makaila talks about going away to school for the first time and how the transition specifically affected her Type 1 diabetes and sleep routine.

Nalani Haviland, MCMSc, PA-C explains the Dawn Phenomenon that some encounter in the morning, and shares tips for both those using MDI and pump therapy.

Lala shares her take on spending much of her life sleeping with diabetes technology and how she deals with it when it gets in the way of her rest.

Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System. 

The FDA announced Wednesday that it has issued a Class 1 recall of Medtronic MiniMed 600 Series insulin pumps, after reports of 2,175 injuries and 1 death.

JDRF President & CEO Aaron Kowalski, Ph.D calls on insurers to cover FDA approved type 1 diabetes technology

Beyond Type 1 chats with Eran Atlas, founder and CEO of DreaMed, a company leveraging revolutionary technology to better diabetes care.

Bob Weishar, founder of Invincible, saw the need to teach non-healthcare personnel at schools all about T1D and how to best support their students.

On December 18, Insulet announced that the Omnipod DASH™ Insulin Management System is now officially available in the UK and the Netherlands. 

Dr. Neinstein was one of four featured experts during Beyond Type 1’s #KnowledgeDrop Series, discussing the future of diabetes care, focusing specifically on technology, data, and emerging therapies.